Figure 4.

Characterization of ADs' effects and cellular targets. (a–d) Top 10 significantly enriched canonical pathways identified with Ingenuity Pathway Analysis (IPA) Software in untreated uCMS rats vs FLX-treated (a), IMIP-treated (b), TIAN-treated (c), and AGOM-treated (d) animals. Pathways presenting the higher number of regulated transcripts were selected. (e) Predicted cell type enrichment and median mRNA half-life (mRNA t½) of uCMS- and ADs-responsive genes. Median mRNA t½ for whole transcriptome was 7.1 h. Error bars denote SEM. *p<0.05; ***p<0.001. AGOM, agomelatine; CT, control; FLX, fluoxetine; IMIP, imipramine; TIAN, tianeptine; uCMS, unpredictable chronic mild stress.